BriaCell Therapeutics Corp.
BCTXW · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $27 | $15 | $8 |
| G&A Expenses | $6 | $0 | $8 | $7 |
| SG&A Expenses | $6 | $6 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$15 |
| Operating Expenses | $27 | $33 | $23 | -$0 |
| Operating Income | -$27 | -$33 | -$23 | -$15 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $28 | $3 | -$12 |
| Pre-Tax Income | -$27 | -$5 | -$27 | -$34 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$26 | -$5 | -$20 | -$12 |
| % Margin | – | – | – | – |
| EPS | -62.6 | -42.99 | -1.74 | -1.73 |
| % Growth | -45.6% | -2,370.7% | -0.6% | – |
| EPS Diluted | -62.6 | -42.99 | -1.74 | -1.73 |
| Weighted Avg Shares Out | 0 | 0 | 16 | 15 |
| Weighted Avg Shares Out Dil | 0 | 0 | 16 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$5 | -$27 | -$34 |
| % Margin | – | – | – | – |